


# UNPACKING THE SKYROCKETING PRICE OF MS DRUGS


Drugmakers are continuing to push the limits on prescription drug prices for a variety of diseases and Multiple Sclerosis (MS) is no exception. Between 2012 and 2017 many MS drugs have nearly doubled in price, driving up the cost of care for all.



## 1 MILLION

PEOPLE LIVING WITH MS  
IN THE UNITED STATES

National Multiple Sclerosis Society



OF MS PATIENTS HAVE TROUBLE AFFORDING THEIR MEDICATION

National Multiple Sclerosis Society



MS WAS THE **FOURTH COSTLIEST** DRUG CLASS IN 2017

Express Scripts

BETASERON	\$48,676	\$91,261
AVONEX	\$44,781	\$86,308
REBIF	\$46,464	\$91,005
GILENYA	\$55,295	\$91,836
COPAXONE	\$51,315	\$91,401

## SAME TREATMENT 2X THE COST

● 2012 ● 2017

National Multiple Sclerosis Society